F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist and 5-HT1A receptor agonist properties: Influence on immediate-early gene expression in rat prefrontal cortex and striatum

European Journal of Pharmacology

Volumn 620, Issue 1-3, 2009, Pages 27-35

  Bruins Slot, Liesbeth A ^a   Lestienne, Fabrice ^a   Grevoz Barret, Catherine ^a   Newman Tancredi, Adrian ^a   Cussac, Didier ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Antipsychotics; c fos; Dopamine D2 receptor; Immediate early gene; Schizophrenia; Serotonin 5 HT1A receptor

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; F 15063; HALOPERIDOL; MESSENGER RNA; N [(2,2 DIMETHYL 2,3 DIHYDROBENZOFURAN 7 YLOXY)ETHYL] 3 (CYCLOPENT 1 ENYL)BENZYLAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; NUCLEAR RECEPTOR NUR77; PROTEIN C FOS; PROTEIN C JUN; PROTEIN ZIF268; SEROTONIN 1A RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOSB; TRANSCRIPTION FACTOR JUNB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION REGULATION; IMMEDIATE EARLY GENE; MALE; NEGATIVE SYNDROME; NONHUMAN; NUCLEOTIDE SEQUENCE; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZOFURANS; BENZYLAMINES; CLOZAPINE; CYCLOPENTANES; DOPAMINE ANTAGONISTS; GENE EXPRESSION REGULATION; GENES, IMMEDIATE-EARLY; HALOPERIDOL; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOSTRIATUM; PIPERAZINES; PREFRONTAL CORTEX; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RNA, MESSENGER; SEROTONIN AGONISTS; TIME FACTORS;

EID: 70349205354     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.08.019     Document Type: Article

References (58)

1. Andersen H.L., and Kilpatrick I.C. Prevention by (+/-)-8-hydroxy-2-(di-n propylamino) tetralin of both catalepsy and rises in rat striatal dopamine metabolism caused by haloperidol. Br. J. Pharmacol. 118 (1996) 421-427
2. 2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice. Naunyn-Schmiedeberg's Arch. Pharmacol. 375 (2007) 241-250
3. 4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release. Eur. J. Pharmacol. 607 (2009) 74-83
4. 1A agonist properties. Neuropsychopharmacology 31 (2006) 1869-1879
5. Beaudry G., Langlois M.C., Weppe I., Rouillard C., and Lévesque D. Constrasting patterns and cellular specificity of transcriptional regulation of the nuclear receptor nerve growth factor-inducible B by haloperidol and clozapine in the rat forebrain. J. Neurochem. 75 (2000) 1694-1702
6. 1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease. Neurobiol. Dis. 23 (2006) 77-86
7. Broekkamp C.L.E., Ossterloo S.K., Berendsen H.H.G., and van Delft A.M.L. Effects of metergoline, fenfluramine, and 8-OH-DPAT on catalepsy induced by haloperidol or morphine. Naunyn-Schmiedeberg's Arch. Pharmacol. 338 (1988) 191-195
8. 1A agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology 49 (2005) 996-1006
9. Claustre Y., Peretti D.D., Brun P., Gueudet C., Allouard N., Alonso R., Lourdelet J., Oblin A., Damoiseau G., Francon D., Suaud-Chagny M.F., Steinberg R., Sevrin M., Schoemaker H., George P., Soubrie P., and Scatton B. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile. Neuropsychopharmacology 28 (2003) 2064-2076
10. Cochran S.M., McKerchar C.E., Morris B.J., and Pratt J.A. Induction of differential patterns of local cerebral glucose metabolism and immediate-early genes by acute clozapine and haloperidol. Neuropharmacology 43 (2002) 394-407
11. Depoortere R., Boulay D., Perrault G., Bergis O., Decobert M., Francon D., Jung M., Simiand J., Soubrie P., and Scatton B. SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity. Neuropsychopharmacology 28 (2003) 1889-1902
12. 4 partial agonist properties : III) activity in models of cognition and negative symtoms. Br. J. Pharmacol. 151 (2007) 266-277
13. 4 partial agonist properties: (II) activity in models of positive symptoms of schizophrenia. Br. J. Pharmacol. 151 (2007) 253-265
14. Deutch A.Y., and Duman R.S. The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization. Neuroscience 70 (1996) 377-389
15. Dragunow M., Robertson G.S., Faull R.L., Robertson H.A., and Jansen K. D2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons. Neuroscience 37 (1990) 287-294
16. Ethier I., Beaudry G., St-Hilaire M., Milbrandt J., Rouillard C., and Lévesque D. The transcription factor NGFI-B (Nur77) and retinoids play a critical role in acute neuroloeptic-induced extrapyramidal effect and striatal neuropeptide gene expression. Neuropsychopharmacology 29 (2004) 335-346
17. 1A receptors. Drugs Fut 27 Suppl A (2002) XVIIth In Symp on Medicinal Chemistry
18. 1A receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 39 (2001) 288-296
19. Grady M.A., Gasperoni T.L., and Kirkpatrick P. Aripiprazole. Nat. Rev. Drug Discov. 2 (2003) 427-428
20. 2 receptor antagonist/partial agonist atypical antipsychotic. Eur. Neuropsychopharmacol. 16 Suppl (2006) P.3.d.006
21. Haleem D.J., Shireen E., and Haleem M.A. Somatodendritic and postsynaptic serotonin-1A receptors in the attenuation of haloperidol-induced catalepsy. Prog. Neuropsychopharm. Biol. Psych. 28 (2004) 1323-1329
22. Ichikawa J., and Meltzer H.Y. The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res. 858 (2000) 252-263
23. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., and Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76 (2001) 1521-1531
24. 1A agonist, blocks haloperidol-induced catalepsy by an action of raphe nuclei medianus and dorsalis. Neuropharmacology 27 (1988) 515-518
25. Jongsma M.E., Sebens J.B., Bosker F.J., and Korf J. Effect of 5-HT augmentation on fos immunoreactivity. Eur. J. Pharmacol. 455 (2002) 109-115
26. Kapur S., Zipursky R., Jones C., Remington G., and Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 157 (2000) 514-520
27. Kleven M.S., Barret-Grévoz C., Bruins Slot L., and Newman-Tancredi A. Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology 49 (2005) 135-143
28. Kontkanen O., Lakso M., Wong G., and Castrén E. Chronic antipsychotic drug treatment induces long-lasting expression of fos and jun family genes and activator protein 1 complex in the rat prefrontal cortex. Neuropsychopharmacology 27 (2002) 152-162
29. 3 receptor selective RGH-1756. Neuropharmacology 40 (2001) 383-393
30. Lévesque D., and Rouillard C. Nur77 and retinoid X receptors: crucial factors in dopamine-related neuroadaptation. Trends Neurosci. 30 (2007) 22-30
31. Littell R.C., Miliken G., Stroup W.W., and Wolfinger R.D. SAS system for mixed models (2000), SAS Institute Inc., SAS Campus Drive, Cary, North Carolina, USA
32. MacGibbon G.A., Lawlor P.A., Bravo R., and Dragunow M. Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja. Mol. Brain Res. 23 (1994) 21-32
33. Maheux J., Ethier I., Rouillard C., and Lévesque D. Induction patterns of transcription factors of the nur family (nurr1, nur77, and nor-1) by typical and atypical antipsychotics in the mouse brain : implication for their mechanism of action. J. Pharmacol. Exp. Ther. 313 (2005) 460-473
34. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 1159-1172
35. Merchant K.M., and Dorsa G.M. Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. Proc. Natl. Acad. Sci. 90 (1993) 3447-3451
36. Millan M.J. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J. Pharmacol. Exp. Ther. 295 (2000) 853-861
37. Miller J.C. Induction of c-fos mRNA expression in rat striatum by neuroleptic drugs. J. Neurochem. 54 (1990) 1453-1455
38. 4 partial agonist properties : I) in vitro receptor affinity and efficacy profile. Br. J. Pharmacol. 151 (2007) 237-252
39. Newman-Tancredi A., Cussac D., and Depoortère R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr. Opin. Investig. Drugs. 8 (2007) 539-554
40. Ohno Y., Shimizu S., Imaki J., Ishihara S., Sofue N., Sasa M., and Kawai Y. Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens. Neuropharmacology 55 (2008) 717-723
41. Palkovits M., and Brownstein M.J. Maps and guide to microdissection of the rat brain (1988), Elsevier Science Publishing, New York, USA
42. Pei Q., Lewis L., Sprakes M.E., Jones E.J., Grahame-Smith D.G., and Zetterstrom T.S.C. Serotonergic regulation of mRNA expression of arc, an immediate early gene selectively localized at neuronal dendrites. Neuropharmacology 39 (2000) 463-470
43. Pei Q., Zetterstrom T.S.C., Sprakes M., Tordera R., and Sharp T. Antidepressant drug treatment induces arc gene expression in the rat brain. Neuroscience 121 (2003) 975-982
44. Pfaffl M.W., Horgan G.W., and Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 30 (2002) 1-10
45. 1A receptor agonist properties. Eur. J. Pharmacol. 356 (1998) 189-192
46. 1A ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology 144 (1999) 20-29
47. 1A receptors. Eur. J. Pharmacol. 395 (2000) 143-147
48. Robertson G.S., and Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46 (1992) 315-328
49. Robertson G.S., Matsumura H., and Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J. Pharmacol. Exp. Ther. 271 (1994) 1058-1066
50. Semba J., Sakai M.Z., Suhara T., and Akanuma N. Differential effects of acute and chronic treatment with typical and atypical neuroleptics on c-fos mRNA expression in rat forebrain regions using non-radioactive in situ hybridization. Neurochem. Int. 34 (1999) 269-277
51. Sgambato-Faure V., Buggia V., Gilbert F., Lévesque D., Benabid A.L., and Berger F. Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats. J. Neuropathol. Exp. Neurol. 64 (2005) 936-947
52. 1A receptor system: possible implications for schizophrenic negative symptomatology. Psychiatr. Ann. 26 (1996) 88-93
53. Shilling P.D., and Feifel D. Decreased haloperidol-induced potentiation of zif268 mRNA expression in the nucleus accumbens shell and the dorsal lateral striatum of rats lacking cholecystokinin-A receptors. Synapse 43 (2002) 134-138
54. 2C receptor activation is differentially regulated in four regions of rat brain. Eur. J. Pharmacol. 307 (1996) 211-217
55. Tremblay P.O., Gervais J., and Rouillard C. Modification of haloperidol-induced pattern of c-fos expression by serotonin agonists. Eur. J. Neurosci. 10 (1998) 3546-3555
56. Vacher, B., Cuisiat, S., Koek, W., Colpaert, F., 2002. 3-(Cyclopenten-1-yl)-benzyl-or 3-(Cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia. Patent # WO 2004/035561 A1. Priority 16 October 2002.
57. 2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology 150 (2000) 422-429
58. Young C.D., Meltzer H.Y., and Deutch A.Y. Effects of desmethylclozapine on fos protein expression in the forebrain: in vivo biological activity of the clozapine metabolite. Neuropsychopharmacology 19 (1998) 99-103